Pharmacogenomics panel test for prevention toxicity in patient who receive Fluoropirimidine/ Oxaliplatin-Based therapy

European Review for Medical and Pharmacological Sciences

Volumn 16, Issue 9, 2012, Pages 1211-1217

  Di Francia, R ^a   Siesto, R S ^a   Valente, D ^b   Sparta D ^c   Berretta, M ^d  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Molecular Diagnostics   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Fluoropirimidine; Genotyping methods; Oxaliplatin; Pharmacogenomics; Toxicity

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C2; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE; FLUOROURACIL; GLUTATHIONE TRANSFERASE; IRINOTECAN; OXALIPLATIN; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; BOLUS INJECTION; CANCER CHEMOTHERAPY; CANCER RESISTANCE; COST BENEFIT ANALYSIS; DRUG TOXICITY; DYSPHONIA; GASTROINTESTINAL TOXICITY; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAND FOOT SYNDROME; HUMAN; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PHARMACOGENOMICS; SENSORY NEUROPATHY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; DIHYDROURACIL DEHYDROGENASE (NADP); FLUOROURACIL; GENOTYPE; HUMANS; ORGANOPLATINUM COMPOUNDS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; THYMIDYLATE SYNTHASE;

EID: 84867960828     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. KIDWELL KM, YOTHERS G, GANZ PA, LAND SR, KO CY, CECCHINI RS, KOPEC JA, WOLMARK N. Long-Term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. Cancer 2012 May 8. [Epub ahead of print]
2. BERRETTA M, ZANET E, NASTI G, LLESHI A, FRUSTACI S, FIORICA F, BEARZ A, TALAMINI R, LESTUZZI C, LAZZARINI R, FISICHELLA R, CANNIZZARO R, IAFFAIOLI RV, BERRETTA S, TIRELLI U. Oxaliplatin-Based chemotherapy in the treatment of elderly patients with metastatic colorectal cancer (CRC). Arch Gerontol Geriatr 2012; 55: 271-275.
3. CECCHIN E, D'ANDREA M, LONARDI S, ZANUSSO C, PELLA N, ERRANTE D, DE MATTIA E, POLESEL J, INNOCENTI F, TOFFOLI G. A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-Fluorouracil/leucovorin/ oxaliplatin (FOLFOX4) regimen. Pharmacogenomics J 2012 Aug 7. [Epub ahead of print].
4. DI FRANCIA R, CIMINO L, BERRETTA M. Genetic variants influencing fluoropyrimidine based-Therapy and available methods to detect them. Eur Rev Med Pharmacol Sci 2012; 16: 285-298.
5. LAMAS MJ, DURAN G, BALBOA E, BERNARDEZ B, TOURIS M, VIDAL Y, GALLARDO E, LOPEZ R, CARRACEDO A, BARROS F. Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-Oxaliplatin regimen in patients with metastatic colorectal cancer. Pharmacogenomics 2011; 12: 433-442.
6. TIRELLI U, BERRETTA M, BEARZ A, CARBONE A. Grouping of molecularly targeted anti-Cancer agents based on cost-Effectiveness analysis. Eur Rev Med Pharmacol Sci 2011; 15: 1355-1356.
7. PAYNE K, SHABARUDDIN FH. Cot-Effectiveness analysis in pharmacogenomics. Pharmacogenomics 2010; 11: 643-646.
8. DHALLA IA, GARNER S, CHALKIDOU K, LITTLEJOHNS P. Perspectives on the National Institute for Health and Clinical Excellence's recommendations to use health technologies only in research. Int J Technol Assess Health Care 2009; 25: 272-280.
9. ZANET E, BERRETTA M, DI BENEDETTO F, TALAMINI R, BALLARIN R, NUNNARI G, BERRETTA S, RIDOLFO A, LLESHI A, ZANGHI A, CAPPELLANI A, TIRELLI U. Pancreatic Cancer in HIV-Positive Patients: A Clinical Case-Control Study. Pancreas 2012 Jun 24 [Epub hhead of print].
10. NASTI G, OTTAIANO A, BERRETTA M, DELRIO P, IZZO F, CASSATA A, ROMANO C, FACCHINI G, SCALA D, MASTROA, ROMANO G, PERRI F, IAFFAIOLI RV. Pre-Operative chemotherapy for colorectal cancer liver metastases: An update of recent clinical trials. Cancer Chemother Pharmacol 2010; 66: 209-218.
11. LEE JJ, KIM TM, YU SJ, KIM DW, JOH YH, OH DY, KWON JH, KIM TY, HEO DS, BANG YJ, KIM NK. Single-Agent capecitabine in patients with metastatic colorectal cancer refractory to 5-Fluorouracil/leucovorin chemotherapy. Jpn J Clin Oncol 2004; 34: 400-404.
12. MAUGHAN TS, JAMES RD, KERR DJ, LEDERMANN JA, MCARDLE C, SEYMOUR MT, COHEN D, HOPWOOD P, JOHNSTON C, STEPHENS RJ; BRITISH MRC COLORECTAL CANCER WORKING PARTY. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: A multicentre randomised trial. Lancet 2002; 359: 1555-1563.
13. BERRETTA M, LLESHI A, DI BENEDETTO F, BEARZ A, SPINA M, TIRELLI U. Oxaliplatin and capecitabine (Xelox) in association with highly active antiretroviral therapy in advanced hepatocarcinoma HIV/HCV-Infected patients. Annals Oncol 2006; 17: 1176-1177.
14. GOLDBERG RM, SARGENT DJ, MORTON RF, FUCHS CS, RAMANATHAN RK, WILLIAMSON SK, FINDLAY BP, PITOT HC, ALBERTS S. Randomized controlled trial of reduceddose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: A North American Intergroup Trial. J Clin Oncol 2006; 24: 3347-3353.
15. BENAVIDES M, PERICAY C, VALLADARES-AYERBES M, GILCALLE S, MASSUTÍ B, APARICIO J, DUEÑAS R, GONZÁLEZFLORES E, CARRATO A, MARCUELLO E, GÓMEZ A, CABRERA E, QUERALT B, GÓMEZ M-J, GUASCH I, ETXEBERRÍA A, ALFARO J, CAMPOS J-M, REINA J-J, ARANDA E. Oxaliplatin in Combination With Infusional 5-Fluorouracil as First-Line Chemotherapy for Elderly Patients With Metastatic Colorectal Cancer: A Phase II Study of the Spanish Cooperative Group for the Treatment of Digestive Tumors. Clin Colorectal Cancer 2012; 11: 200-206.
16. IBRAHIM A, HIRSCHFELD S, COHEN MH, GRIEBEL DJ, WILLIAMS GA, PAZDUR R. FDA drug approval summaries: Oxaliplatin. Oncologist 2004; 9: 8-12.
17. BERRETTA M, TAIBI R, BEARZ A, LA MURA N, BERRETTA S, TIRELLI U, FRUSTACI S. Dysphonia as an unusual toxic event of oxaliplatin-Based chemotherapy. J Chemother 2004; 16: 595-598.
18. BEARZ A, GARASSINO I, TISEO M, CAFFO O, SOTO-PARRA H, BOCCALON M, TALAMINI R, SANTORO A, BARTOLOTTI M, MURGIA V, BERRETTA M, TIRELLI U. Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer. Lung Cancer 2010; 68: 264-268.
19. BERRETTA M, BEARZ A, FRUSTACI S, TALAMINI R, LOMBARDI D, FRATINO L, LLESHI A, BONANNO S, SPARTÀ D, PALMUCCI S, BERRETTA S, TIRELLI U. FOLFOX2 in the treatment of advanced colorectal cancer: A comparison between elderly and middle aged patients. J Chemother 2008; 20: 503-508.
20. BERRETTA M, LLESHI A, CAPPELLANI A, BEARZ A, SPINA M, TALAMINI R, CACOPARDO B, NUNNARI G, MONTESARCHIO V, IZZI I, LANZAFAME M, NASTI G, BASILE F, BERRETTA S, FISICHELLA R, SCHIANTARELLI CC, GARLASSI E, RIDOLFO A, GUELLA L, TIRELLI U. Oxaliplatin based chemotherapy and concomitant highly active antiretroviral therapy in the treatment of 24 patients with colorectal cancer and HIV infection. Curr HIV Res 2010; 8: 218-222.
21. BERRETTA M, DI BENEDETTO F, BEARZ A, SIMONELLI C, MARTELLOTTA F, DEL BEN C, BERRETTA S, SPINA M, TIRELLI U. FOLFOX-4 regimen with concomitant highly active antiretroviral therapy in metastatic colorectal cancer HIV-Infected patients: A report of five cases and review of the literature. Cancer Invest 2008; 26: 610-614.
22. BERRETTA M, CAPPELLANI A, FIORICA F, NASTI G, FRUSTACI S, FISICHELLA R, BEARZ A, TALAMINI R, LLESHI A, TAMBARO R, COCCIOLO A, RISTAGNO M, BOLOGNESE A, BASILE F, MENEGUZZO N, BERRETTA S, TIRELLI U. FOLFOX4 in the treatment of metastatic colorectal cancer in elderly patients: A prospective study. Arch Gerontol Geriatr 2011; 52: 89-93.
23. YEN J-L, MCLEOD H-L. Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer 2007; 43: 1011-1016.
24. OGURA K: [Dihydropyrimidine dehydrogenase activity and its genetic aberrations]. Gan To Kagaku Ryoho 2006; 33: 1041-1048.
25. SAIF MW, EZZELDIN H, VANCE K, SELLERS S, DIASIO RB. DPYD.*2A mutation: The most common mutation associated with DPD deficiency. Cancer Chemother Pharmacol 2007; 60: 503-507.
26. OKAMOTO Y, UETA A, SUMI S, ITO T, OKUBO Y, JOSE Y, NINOMIYA A, TOGARI H, NISHIDA M. SSCP screening of the dihydropyrimidine dehydrogenase gene polymorphisms of the Japanese population using a semi-Automated electrophoresis unit. Biochem Genet 2007; 45: 713-724.
27. MOREL A, BOISDRON-CELLE M, FEY L, LAINÉ-CESSAC P, GAMELIN E. Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-Fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma. Clin Biochem 2007; 40: 11-17.
28. BOSCH TM, BAKKER R, SCHELLENS JH, CATS A, SMITS PH, BEIJNEN JH. Rapid detection of the DPYD IVS14+1G>A mutation for screening patients to prevent fluorouracil-Related toxicity. Mol Diagn Ther 2007; 11: 105-108.
29. LECOMTE T, FERRAZ JM, ZINZINDOHOUE F, ZINZINDOHOUÉ F, LORIOT MA, TREGOUET DA, LANDI B, BERGER A, CUGNENC PH, JIAN R, BEAUNE P, LAURENT-PUIG P. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-Fluorouracil-Based chemotherapy. Clin Cancer Res 2004; 10: 5880-5888.
30. LECOMTE T, LANDI B, BEAUNE P, LAURENT-PUIG P, LORIOT MA. Glutathione S-Transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-Based chemotherapy. Clin Cancer Res 2006; 12: 3050-3056.
31. GEORGIADIS P, DEMOPOULOS N-A, TOPINKA J, STEPHANOU G, STOIKIDOU M, BEKYROU M, KATSOUYIANNI K, SRAM R, AUTRUP H, KYRTOPOULOS SA. Impact of phase I or phase II enzyme polymorphisms on lymphocyte DNA adducts in subjects exposed to urban air pollution and environmental tobacco smoke. Toxicol Lett 2004; 149: 269-280.
32. RUZZO A, GRAZIANO F, LOUPAKIS F, RULLI E, CANESTRARI E, SANTINI D, CATALANO V, FICARELLI R, MALTESE P, BISONNI R, MASI G, SCHIAVON G, GIORDANI P, GIUSTINI L, FALCONE A, TONINI G, SILVA R, MATTIOLI R, FLORIANI I, MAGNANI M. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-Line FOLFOX-4 chemotherapy. J Clin Oncol 2007; 25: 1247-1254.
33. MCLEOD HL, SARGENT DJ, MARSH S, GREEN EM, KING CR, FUCHS CS, RAMANATHAN RK, WILLIAMSON SK, FINDLAY BP, THIBODEAU SN, GROTHEY A, MORTON RF, GOLDBERG RM. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: Results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol 2010; 28: 3227-3233
34. BALBOA S, BERMUDEZ-CRESPO J, GIANZO C, LÓPEZ JL, ROMALDE JL. Proteomics and multilocus sequence analysis confirm intraspecific variability of Vibrio tapetis. FEMS Microbiol Lett 2011; 324: 80-87.
35. FONTANA L, DELORT L, JOUMARD L, RABIAU N, BOSVIEL R, SATIH S, GUY L, BOITEUX JP, BIGNON YJ, CHAMOUX A, BERNARD-GALLON DJ. Genetic polymorphisms in CYP1A1, CYP1B1, COMT, GSTP1 and NAT2 genes and association with bladder cancer risk in a French cohort. Anticancer Res 2009; 29: 1631-1635.
36. NORAMBUENA PA, COPELAND JA, KRENKOVA P, STAMBERGOVÁ A, MACEK M Jr. Diagnostic method validation: High resolution melting (HRM) of small amplicons genotyping for the most common variants in the MTHFR gene. Clin Biochem 2009; 42: 1308-1316.
37. HAENISCH S, MAY K, WEGNER D, CALIEBE A, CASCORBI I, SIEGMUND W. Influence of genetic polymorphisms on intestinal expression and rifampicin-Type induction of ABCC2 and on bioavailability of talinolol. Pharmacogenet Genomics 2008; 18: 357-365.
38. BEARZ A, VACCHER E, TALAMINI R, BERRETTA M, TIRELLI U. Comment on 'Lung cancer in the Swiss HIV Cohort Study: Role of smoking, immunodeficiency and pulmonary infection'. Br J Cancer 2012; 106:1899-1900
39. CAMILLERI M, SAITO YA. Pharmacogenomics in gastrointestinal disorders. Methods Mol Biol 2008; 448: 395-412.
40. CEPPI P, VOLANTE M, FERRERO A, RIGHI L, RAPA I, ROSAS R, BERRUTI A, DOGLIOTTI L, SCAGLIOTTI GV, PAPOTTI M. Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 2008; 14: 1059-1064.
41. BERRETTA M, CAPPELLANI A, DI BENEDETTO F, LLESHI A, TALAMINI R, CANZONIERI V, ZANET E, BEARZ A, NASTI G, LACCHIN T, BERRETTA S, FISICHELLA R, BALESTRERI L, TORRESIN A, IZZI I, ORTOLANI P, TIRELLI U. Clinical presentation and outcome of colorectal cancer in HIVpositive patients: A clinical case-Control study. Onkologie 2009; 32: 319-324.
42. PARK DJ, ZHANG W, STOEHLMACHER J, TSAO-WEI D, GROSHEN S, GIL J, YUN J, SONES E, MALLIK N, LENZ HJ. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-Based chemotherapy. Clin Adv Hematol Oncol 2003; 1: 162-166.
43. GIACALONE A, SPINA M, BERRETTA M, TIRELLI U. Two types of fatigue in cancer patients. Br J Cancer 2012; 106: 424; author reply 425.
44. CAPPELLANI A, CAVALLARO A, DI VITA M, ZANGHI A, PICCOLO G, LO MENZO E, CAVALLARO V, MALAGUARNERA M, GIAQUINTA A, VEROUX M, CIMINO L, BERRETTA M. Diet and pancreatic cancer: Many questions with few certainties. Eur Rev Med Pharmacol Sci 2012; 16: 192-206.
45. VAN DEN AKKER-VAN MARLE ME, GURWITZ D, DETMAR SB, ENZING CM, HOPKINS MM, GUTIERREZ DE MESA E, IBARRETA D. Cost-Effectiveness of pharmacogenomics in clinical practice: A case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics 2006; 7: 783-792.
46. DI FRANCIA R, BERRETTA M, CATAPANO O, CANZONIERO LM, FORMISANO L. Molecular diagnostics for pharmacogenomic testing of fluoropyrimidine basedtherapy: Costs, methods and applications. Clin Chem Lab Med 2011; 49: 1105-1111.
47. DI FRANCIA R, FRIGERI F, BERRETTA M, CECCHIN E, ORLANDO C, PINTO A, PINZANI P. Decision criteria for rational selection of homogeneous genotyping platforms for pharmacogenomics testing in clinical diagnostics. Clin Chem Lab Med 2010; 48:447-459.
48. DI FRANCIA R, VALENTE D, CATAPANO O, RUPOLO M, TIRELLI U, BERRETTA M. Knowledge and skills needs for health professions about pharmacogenomics testing field. Eur Rev Med Pharmacol Sci 2012; 16: 781-788.
49. TIRELLI U, BERRETTA M, SPINA M, MICHIELI M, LAZZARINI R. Oncologic drug shortages also in Italy. Eur Rev Med Pharmacol Sci 2012, 16: 138-139.
50. BERRETTA M, LLESHI A, FISICHELLA R, BERRETTA S, BASILE F, LI VOLTI G, BOLOGNESE A, BIONDI A, DE PAOLI P, TIRELLI U, CAPPELLANI A. The role of nutrition in the development of esophageal cancer: What do we know? Front Biosci (Elite Ed) 2012; 4: 351-357.
51. BERRETTA M, CAPPELLANI A, LLESHI A, DI VITA M, LO MENZO E, BEARZ A, GALVANO F, SPINA M, MALAGUARNERA M, TIRELLI U, BERRETTA S. The role of diet in gastric cancer: Still an open question. Front Biosci 2012; 17: 1640-1647.
52. CAPPELLANI A, DI VITA M, ZANGHI A, CAVALLARO A, PICCOLO G, VEROUX M, BERRETTA M, MALAGUARNERA M, CANZONIERI V, LO MENZO E. Diet, obesity and breast cancer: An update Front Biosci (Schol Ed) 2012; 4: 90-108.
53. ZHANG H, LI YM, ZHANG H, JIN X. DPYD 5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: Results from genotyping study on 75 gastric carcinoma and colon carcinoma patients. Med Oncol 2007; 24: 251-258.
54. GUSELLA M, FRIGO AC, BOLZONELLA C, MARINELLI R, BARILE C, BONONI A, CREPALDI G, MENON D, STIEVANO L, TOSO S, PASINI F, FERRAZZI E, PADRINI R. Predictors of survival and toxicity in patients on adjuvant therapy with 5-Fluorouracil for colorectal cancer. Br J Cancer 2009; 100: 1549-1557.
55. BALBOA E, DURAN G, LAMAS MJ, GOMEZ-CAAMAÑO A, CELEIRO-MUÑOZ C, LOPEZ R, CARRACEDO A, BARROS F. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: High incidence of somatic mutations and their relation with response. Pharmacogenomics 2010; 11: 747-761.